Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
New Enterprise Associates
AddedApr 23, 2026
UpdatedJul 2, 2026
New Enterprise Associates

New Enterprise Associates

Operating

New Enterprise Associates is a global venture capital firm investing in technology and healthcare companies from seed to IPO.

Location
Menlo Park, CA, US
Founded
1977
Firm
Analysis
Compare
Portfolio
Employees
News
Website

Investments

Twelve Labs
Twelve Labs
Series B

Total Raised

$127.1M

Rounds

5

Series B$100MJuly 2026
Seed$10MOctober 2023
Aurelian
Aurelian
Series A

Total Raised

$14.5M

Rounds

2

Series A$14MAugust 2025
ElevenLabs
ElevenLabs

Total Raised

$781M

Rounds

6

Series C$180MJanuary 2025
Synthesia
Synthesia
Series D

Total Raised

$336.6M

Rounds

6

Series D$180MJanuary 2025
Sana
Sana
Acquired Subsidiary

Total Raised

$1.2B

Rounds

3

Series C$55MOctober 2024
Series B$62MMay 2023
World Labs
World Labs
Series B

Total Raised

$1.2B

Rounds

2

Series A$230MSeptember 2024
Sakana AI
Sakana AI
Series B

Total Raised

$32.2B

Rounds

2

Series A$200MSeptember 2024
Clio
Clio
Series F

Total Raised

$1.3B

Rounds

6

Series F$900MJuly 2024
Xaira Therapeutics
Xaira Therapeutics
Series A

Total Raised

$1B

Rounds

1

Series A$1BApril 2024
Second Front Systems
Second Front Systems

Total Raised

$82.1M

Rounds

7

Series UnknownJanuary 2024
Perplexity AI
Perplexity AI
Series D

Total Raised

$802.3M

Rounds

5

Series B$73.6MJanuary 2024
Series A$25.6MMarch 2023
Together AI
Together AI
Series C

Total Raised

$1.2B

Rounds

4

Series A$102.5MNovember 2023
Pulumi
Pulumi

Total Raised

$98.5M

Rounds

4

Series C$41MOctober 2023
Fizz
Fizz

Total Raised

$41.5M

Rounds

3

Series B$25MAugust 2023
Series A$12MNovember 2022
Seed$4.5MOctober 2022
Strive Health
Strive Health

Total Raised

$386M

Rounds

3

Series C$166MMay 2023
Ledge
Ledge

Total Raised

$9M

Rounds

2

Seed$9MFebruary 2023
Pre-SeedJuly 2022
Escient Pharmaceuticals
Escient Pharmaceuticals
Public

Total Raised

$237.5M

Rounds

3

Series C$120MNovember 2022
MBX Biosciences
MBX Biosciences

Total Raised

$174.9M

Rounds

3

Series B$115MNovember 2022
Merge
Merge

Total Raised

$74.5M

Rounds

3

Series B$55MOctober 2022